Blood Levels of Biomarker (GFAP) May Predict Dementia Risk in Mexican Americans, Study Suggests

Blood levels of a biomarker called glial fibrillary acidic protein (GFAP) may uniquely aid prediction of dementia in Mexican Americans, researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and collaborating institutions reported on March 24, 2022. The team scrutinized conversion to dementia over an average four years of follow-up in 745 Mexican Americans participating in the Texas Alzheimer’s Research and Care Consortium (TARCC) study. The research is described in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, a journal of the Alzheimer’s Association. The open-access article is titled “Blood Biomarkers for Cognitive Decline and Clinical Progression in a Mexican American Cohort.”

Login Or Register To Read Full Story